Pharmaceutical

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Solid Tumor: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Solid Tumor.

Apr 19, 2024 - 00:00
SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Solid Tumor.
Read the original article

Tags:

Previous Article

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Peritoneal Cancer: Likel...

Next Article

Rigosertib sodium by Traws Pharma for Epidermolysis Bullosa: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Eli Lilly achieving significant gains in obesity results

Eli Lilly achieving significant gains in obesity results

Jun 7, 2023

STAT+: Novocure’s electric fields device prolongs survival in lung cancer, but doubts remain

STAT+: Novocure’s electric fields device prolongs survi...

Jun 6, 2023

Moderna and Mitsubishi Tanabe link on mRNA vaccines in Japan

Moderna and Mitsubishi Tanabe link on mRNA vaccines in ...

Jul 10, 2024